B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
BHC
Bausch Health CompaniesANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 consolidated revenue rose 13% year over year to $2.85 billion, with 11% organic growth; the company raised its 2026 outlook. Continued Salix growth and cash generation would support an upside case.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Cash conversion and net-debt reduction may prove uneven; Q2 alone does not establish a durable trend. [#SEC-8K-2026-07-29]
Momentum
90
Value
71
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.60 · Bull $8.50 · Bear $4.70Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum90 · Δ7d +15.2
Value71 · Δ7d -0.2
Sentiment54 · Δ7d -4.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Cash conversion and net-debt reduction may prove uneven; Q2 alone does not establish a durable trend. [#SEC-8K-2026-07-29]
- • No current analyst revisions, verified recent-news tone or post-Q3 market reaction are available.
- • A slowdown in Xifaxan or weaker cash conversion could undermine the raised outlook and limit debt reduction.
Catalyst clock
2026-10-28
October 28 third-quarter results
Lead driver: Value · See fundamentals
Momentum
90
8% active weight
Current posture
7d trendImproving
Δ7d
+15.2
Δ21d
+54.8
Value
71
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
54
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-16.4
Why this grade
Composite grade A. Momentum 90.2 / Value 70.6 / Sentiment 53.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$6.60
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.70
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$2.41B
Beta
0.43
Shares Out
373.99M
P/E (TTM)
7.7
P/S (TTM)
0.27
P/FCF (TTM)
2.54
Rev YoY
+12.7%
EPS YoY
+72.0%
Gross Margin
+63.0%
Op Margin
+25.2%
Net Debt
$19.75B
Current Ratio
1.44
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data